Pretransplant Serum Ferritin Levels and Outcomes after Myeloablative Allogeneic HSCT
Eastern Journal Of Medicine · 2026 · 31 (4) · 779-788
DOI: 10.5505/ejm.2026.76032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Eastern Journal Of Medicine, 2026. Verfasst von Burcu Aslan Candır und 11 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Candır, B. A., Seçilmiş, S., Yaman, S., BOZAN, E., Ulu, B. U., İSKENDER, D., Yiğenoğlu, T. N., Çakar, M. K., Ulas, T., DAL, M. S., Altuntas, F., & Altuntas, F. (2026). Pretransplant Serum Ferritin Levels and Outcomes after Myeloablative Allogeneic HSCT. Eastern Journal Of Medicine, 31(4), 779-788. https://doi.org/10.5505/ejm.2026.76032
Vancouver
Candır BA, Seçilmiş S, Yaman S, BOZAN E, Ulu BU, İSKENDER D, et al. Pretransplant Serum Ferritin Levels and Outcomes after Myeloablative Allogeneic HSCT. Eastern Journal Of Medicine. 2026;31(4):779-788. doi:10.5505/ejm.2026.76032
BibTeX
@article{Candr2026,
author = {Candır, Burcu Aslan and Seçilmiş, Sema and Yaman, Samet and BOZAN, Ersin and Ulu, Bahar Uncu and İSKENDER, DİCLE and Yiğenoğlu, Tuğçe Nur and Çakar, Merih Kızıl and Ulas, Turgay and DAL, MEHMET SINAN and Altuntas, Fevzi and Altuntas, Fevzi},
title = {Pretransplant Serum Ferritin Levels and Outcomes after Myeloablative Allogeneic HSCT},
journal = {Eastern Journal Of Medicine},
year = {2026},
volume = {31},
number = {4},
pages = {779--788},
doi = {10.5505/ejm.2026.76032}
}
EUVIMED